|
1
|
Tammemagi MC, Berg CD, Riley TL,
Cunningham CR and Taylor KL: Impact of lung cancer screening
results on smoking cessation. J Natl Cancer Inst. 106:dju0842014.
View Article : Google Scholar
|
|
2
|
Sun S, Schiller JH and Gazdar AF: Lung
cancer in never smokers-a different disease. Nat Rev Cancer.
7:778–790. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Relli V, Trerotola M, Guerra E and Alberti
S: Abandoning the notion of non-small cell lung cancer. Trends Mol
Med. 25:585–594. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng H, Zhan Y, Liu S, Lu J, Luo J, Feng
J and Fan S: The roles of tumor-derived exosomes in non-small cell
lung cancer and their clinical implications. J Exp Clin Cancer Res.
37:2262018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fernandez Y, Viesca M and Arvanitakis M:
Early diagnosis and management of malignant distal biliary
obstruction: A review on current recommendations and guidelines.
Clin Exp Gastroenterol. 12:415–432. 2019. View Article : Google Scholar
|
|
6
|
Murphy RM, Watt MJ and Febbraio MA:
Metabolic communication during exercise. Nat Metab. 2:805–816.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gururaja Rao S: Mitochondrial changes in
cancer. Handb Exp Pharmacol. 240:211–227. 2017. View Article : Google Scholar
|
|
8
|
Chen Y, Chen Z, Feng JH, Chen YB, Liao NS,
Su Y and Zou CY: Metabolic profiling of normal hepatocyte and
hepatocellular carcinoma cells via 1H nuclear magnetic
resonance spectroscopy. Cell Biol Int. 42:425–434. 2018. View Article : Google Scholar
|
|
9
|
Guppy M: The hypoxic core: A possible
answer to the cancer paradox. Biochem Biophys Res Commun.
299:676–680. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kalyanaraman B: Teaching the basics of
cancer metabolism: Developing antitumor strategies by exploiting
the differences between normal and cancer cell metabolism. Redox
Biol. 12:833–842. 2017. View Article : Google Scholar
|
|
11
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moretti M, Bennett J, Tornatore L,
Thotakura AK and Franzoso G: Cancer: NF-κB regulates energy
metabolism. Int J Biochem Cell Biol. 44:2238–2243. 2012. View Article : Google Scholar
|
|
14
|
Courtnay R, Ngo DC, Malik N, Ververis K,
Tortorella SM and Karagiannis TC: Cancer metabolism and the Warburg
effect: The role of HIF-1 and PI3K. Mol Biol Rep. 42:841–851. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Christofk HR, Vander Heiden MG, Harris MH,
Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ward PS and Thompson CB: Metabolic
reprogramming: A cancer hallmark even warburg did not anticipate.
Cancer Cell. 21:297–308. 2012. View Article : Google Scholar
|
|
17
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar
|
|
19
|
Nagao A, Kobayashi M, Koyasu S, Chow CCT
and Harada H: HIF-1-dependent reprogramming of glucose metabolic
pathway of cancer cells and its therapeutic significance. Int J Mol
Sci. 20:2382019. View Article : Google Scholar
|
|
20
|
Musharraf SG, Mazhar S, Choudhary MI, Rizi
N and Atta-ur-Rahman: Plasma metabolite profiling and chemometric
analyses of lung cancer along with three controls through gas
chromatography-mass spectrometry. Sci Rep. 5:86072015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patra KC and Hay N: The pentose phosphate
pathway and cancer. Trends Biochem Sci. 39:347–354. 2014.
View Article : Google Scholar
|
|
23
|
Lam C, Low JY, Tran PT and Wang H: The
hexosamine biosynthetic pathway and cancer: Current knowledge and
future therapeutic strategies. Cancer Lett. 503:11–18. 2021.
View Article : Google Scholar
|
|
24
|
Amelio I, Cutruzzola F, Antonov A,
Agostini M and Melino G: Serine and glycine metabolism in cancer.
Trends Biochem Sci. 39:191–198. 2014. View Article : Google Scholar
|
|
25
|
Liu Y, Cao Y, Zhang W, Bergmeier S, Qian
Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, et al: A small-molecule
inhibitor of glucose transporter 1 downregulates glycolysis,
induces cell-cycle arrest, and inhibits cancer cell growth in vitro
and in vivo. Mol Cancer Ther. 11:1672–1682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu S and Herschman HR: A tumor agnostic
therapeutic strategy for hexokinase 1-Null/Hexokinase 2-positive
cancers. Cancer Res. 79:5907–5914. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang XY, Zhang M, Cong Q, Zhang MX, Zhang
MY, Lu YY and Xu CJ: Hexokinase 2 confers resistance to cisplatin
in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Int J Biochem Cell Biol. 95:9–16. 2018. View Article : Google Scholar
|
|
28
|
Maschek G, Savaraj N, Priebe W,
Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR and Lampidis
TJ: 2-deoxy-D-glucose increases the efficacy of adriamycin and
paclitaxel in human osteosarcoma and non-small cell lung cancers in
vivo. Cancer Res. 64:31–34. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim SM, Yun MR, Hong YK, Solca F, Kim JH,
Kim HJ and Cho BC: Glycolysis inhibition sensitizes non-small cell
lung cancer with T790M mutation to irreversible EGFR inhibitors via
translational suppression of Mcl-1 by AMPK activation. Mol Cancer
Ther. 12:2145–2156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin S, Li Y, Wang D, Huang C, Marino D,
Bollt O, Wu C, Taylor MD, Li W, DeNicola GM, et al: Fascin promotes
lung cancer growth and metastasis by enhancing glycolysis and
PFKFB3 expression. Cancer Lett. 518:230–242. 2021. View Article : Google Scholar
|
|
31
|
Shen J, Jin Z, Lv H, Jin K, Jonas K, Zhu C
and Chen B: PFKP is highly expressed in lung cancer and regulates
glucose metabolism. Cell Oncol (Dordr). 43:617–629. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo W, Zhang Y, Chen T, Wang Y, Xue J,
Zhang Y, Xiao W, Mo X and Lu Y: Efficacy of RNAi targeting of
pyruvate kinase M2 combined with cisplatin in a lung cancer model.
J Cancer Res Clin Oncol. 137:65–72. 2011. View Article : Google Scholar
|
|
33
|
Shi HS, Li D, Zhang J, Wang YS, Yang L,
Zhang HL, Wang XH, Mu B, Wang W, Ma Y, et al: Silencing of pkm2
increases the efficacy of docetaxel in human lung cancer xenografts
in mice. Cancer Sci. 101:1447–1453. 2010. View Article : Google Scholar
|
|
34
|
Morita M, Sato T, Nomura M, Sakamoto Y,
Inoue Y, Tanaka R, Ito S, Kurosawa K, Yamaguchi K, Sugiura Y, et
al: PKM1 confers metabolic advantages and promotes cell-autonomous
tumor cell growth. Cancer Cell. 33:355–367. e72018. View Article : Google Scholar
|
|
35
|
Israelsen WJ and Vander Heiden MG:
Pyruvate kinase: Function, regulation and role in cancer. Semin
Cell Dev Biol. 43:43–51. 2015. View Article : Google Scholar
|
|
36
|
Zhang X, Guo M, Fan J, Lv Z, Huang Q, Han
J, Wu F, Hu G, Xu J and Jin Y: Prognostic significance of serum LDH
in small cell lung cancer: A systematic review with meta-analysis.
Cancer Biomark. 16:415–423. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Costa Leite T, Da Silva D, Guimaraes
Coelho R, Zancan P and Sola-Penna M: Lactate favours the
dissociation of skeletal muscle 6-phosphofructo-1-kinase tetramers
down-regulating the enzyme and muscle glycolysis. Biochem J.
408:123–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hui S, Ghergurovich JM, Morscher RJ, Jang
C, Teng X, Lu W, Esparza LA, Reya T, Le Zhan, Yanxiang Guo J, et
al: Glucose feeds the TCA cycle via circulating lactate. Nature.
551:115–118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Colegio OR, Chu NQ, Szabo AL, Chu T,
Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC,
Phillips GM, et al: Functional polarization of tumour-associated
macrophages by tumour-derived lactic acid. Nature. 513:559–563.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP,
Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, et al: Overcoming
trastuzumab resistance in breast cancer by targeting dysregulated
glucose metabolism. Cancer Res. 71:4585–4597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al: Warburg
effect in chemosensitivity: Targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Faubert B, Li KY, Cai L, Hensley CT, Kim
J, Zacharias LG, Yang C, Do QN, Doucette S, Burguete D, et al:
Lactate metabolism in human lung tumors. Cell. 171:358–371. e92017.
View Article : Google Scholar
|
|
43
|
Hensley CT, Faubert B, Yuan Q, Lev-Cohain
N, Jin E, Kim J, Jiang L, Ko B, Skelton R, Loudat L, et al:
Metabolic heterogeneity in human lung tumors. Cell. 164:681–694.
2016. View Article : Google Scholar
|
|
44
|
Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu
RM, Bernard K, Thannickal VJ and Liu G: Glycolytic reprogramming in
myofibroblast differentiation and lung fibrosis. Am J Respir Crit
Care Med. 192:1462–1474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chang YC, Chan YC, Chang WM, Lin YF, Yang
CJ, Su CY, Huang MS, Wu ATH and Hsiao M: Feedback regulation of
ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer
progression. Cancer Lett. 403:28–36. 2017. View Article : Google Scholar
|
|
46
|
Romero OA, Torres-Diz M, Pros E, Savola S,
Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, et
al: MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF
programs and is synthetic lethal with BRG1. Cancer Discov.
4:292–303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
de Koning TJ: Amino acid synthesis
deficiencies. J Inherit Metab Dis. 40:609–620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cluntun AA, Lukey MJ, Cerione RA and
Locasale JW: Glutamine metabolism in cancer: Understanding the
heterogeneity. Trends Cancer. 3:169–180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Altman BJ, Stine ZE and Dang CV: From
Krebs to clinic: Glutamine metabolism to cancer therapy. Nat Rev
Cancer. 16:7732016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Scalise M, Pochini L, Galluccio M, Console
L and Indiveri C: Glutamine transport and mitochondrial metabolism
in cancer cell growth. Front Oncol. 7:3062017. View Article : Google Scholar
|
|
51
|
Serizawa M, Kusuhara M, Zangiacomi V,
Urakami K, Watanabe M, Takahashi T, Yamaguchi K, Yamamoto N and Koh
Y: Identification of metabolic signatures associated with erlotinib
resistance of non-small cell lung cancer cells. Anticancer Res.
34:2779–2787. 2014.PubMed/NCBI
|
|
52
|
Dunphy MPS, Harding JJ, Venneti S, Zhang
H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK,
Staton K, et al: In vivo PET assay of tumor glutamine flux and
metabolism: In-Human Trial of
18F-(2S,4R)-4-Fluoroglutamine. Radiology. 287:667–675.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jeon SM, Chandel NS and Hay N: AMPK
regulates NADPH homeostasis to promote tumour cell survival during
energy stress. Nature. 485:661–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yu Y, Newman H, Shen L, Sharma D, Hu G,
Mirando AJ, Zhang H, Knudsen E, Zhang GF, Hilton MJ and Karner CM:
Glutamine metabolism regulates proliferation and lineage allocation
in skeletal stem cells. Cell Metab. 29:966–978. e42019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Simon J, Nunez-Garcia M, Fernandez-Tussy
P, Barbier-Torres L, Fernández-Ramos D, Gómez-Santos B, Buqué X,
Lopitz-Otsoa F, Goikoetxea-Usandizaga N, Serrano-Macia M, et al:
Targeting hepatic glutaminase 1 ameliorates non-alcoholic
steatohepatitis by restoring very-low-density lipoprotein
triglyceride assembly. Cell Metab. 31:605–622. e102020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mates JM, Campos-Sandoval JA and Marquez
J: Glutaminase isoenzymes in the metabolic therapy of cancer.
Biochim Biophys Acta Rev Cancer. 1870:158–164. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Daemen A, Liu B, Song K, Kwong M, Gao M,
Hong R, Nannini M, Peterson D, Liederer BM, de la Cruz C, et al:
Pan-Cancer metabolic signature predicts co-dependency on
glutaminase and de novo glutathione synthesis linked to a
high-mesenchymal cell state. Cell Metab. 28:383–399. e3892018.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Han T, Zhan W, Gan M, Liu F, Yu B, Chin YE
and Wang JB: Phosphorylation of glutaminase by PKCε is essential
for its enzymatic activity and critically contributes to
tumorigenesis. Cell Res. 28:655–669. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jacque N, Ronchetti AM, Larrue C, Meunier
G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M,
et al: Targeting glutaminolysis has antileukemic activity in acute
myeloid leukemia and synergizes with BCL-2 inhibition. Blood.
126:1346–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
van den Heuvel AP, Jing J, Wooster RF and
Bachman KE: Analysis of glutamine dependency in non-small cell lung
cancer: GLS1 splice variant GAC is essential for cancer cell
growth. Cancer Biol Ther. 13:1185–1194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu
EL, Muhammad N, Rhyne S, Li K, Haloul M, et al: The hexosamine
biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant
lung cancer. Nat Metab. 2:1401–1412. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sezgin E, Levental I, Mayor S and Eggeling
C: The mystery of membrane organization: Composition, regulation
and roles of lipid rafts. Nat Rev Mol Cell Biol. 18:361–374. 2017.
View Article : Google Scholar
|
|
63
|
Snaebjornsson MT, Janaki-Raman S and
Schulze A: Greasing the wheels of the cancer machine: The role of
lipid metabolism in cancer. Cell Metab. 31:62–76. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Menendez JA and Lupu R: Fatty acid
synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Corbet C and Feron O: Cancer cell
metabolism and mitochondria: Nutrient plasticity for TCA cycle
fueling. Biochim Biophys Acta Rev Cancer. 1868:7–15. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Svensson RU, Parker SJ, Eichner LJ, Kolar
MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A,
Vera L, et al: Inhibition of acetyl-CoA carboxylase suppresses
fatty acid synthesis and tumor growth of non-small-cell lung cancer
in preclinical models. Nat Med. 22:1108–1119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tadros S, Shukla SK, King RJ, Gunda V,
Vernucci E, Abrego J, Chaika NV, Yu F, Lazenby AJ, Berim L, et al:
De novo lipid synthesis facilitates gemcitabine resistance through
endoplasmic reticulum stress in pancreatic cancer. Cancer Res.
77:5503–5517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Buckley D, Duke G, Heuer TS, O'Farrell M,
Wagman AS, McCulloch W and Kemble G: Fatty acid synthase-Modern
tumor cell biology insights into a classical oncology target.
Pharmacol Ther. 177:23–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Currie E, Schulze A, Zechner R, Walther TC
and Farese RV Jr: Cellular fatty acid metabolism and cancer. Cell
Metab. 18:153–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Shen M, Tsai Y, Zhu R, Keng PC, Chen Y,
Chen Y and Lee SO: FASN-TGF-β1-PD-L1 axis contributes to the
development of resistance to NK cell cytotoxicity of
cisplatin-resistant lung cancer cells. Biochim Biophys Acta Mol
Cell Biol Lipids. 1863:313–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ali A, Levantini E, Teo JT, Goggi J,
Clohessy JG, Wu CS, Chen L, Yang H, Krishnan I, Kocher O, et al:
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated
non-small cell lung cancer. EMBO Mol Med. 10:e83132018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Falchook G, Infante J, Arkenau HT, Patel
MR, Dean E, Borazanci E, Brenner A, Cook N, Lopez J, Pant S, et al:
First-in-human study of the safety, pharmacokinetics, and
pharmacodynamics of first-in-class fatty acid synthase inhibitor
TVB-2640 alone and with a taxane in advanced tumors.
EClinicalMedicine. 34:1007972021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jones SF and Infante JR: Molecular
pathways: Fatty acid synthase. Clin Cancer Res. 21:5434–5438. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Dang L, Yen K and Attar EC: IDH mutations
in cancer and progress toward development of targeted therapeutics.
Ann Oncol. 27:599–608. 2016. View Article : Google Scholar
|
|
75
|
Chen C, Liu Y, Lu C, Cross JR, Morris JP
IV, Shroff AS, Ward PS, Bradner JE, Thompson C and Lowe SW:
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that
is susceptible to Brd4 inhibition. Genes Dev. 27:1974–1985. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Migita T, Narita T, Nomura K, Miyagi E,
Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y,
et al: ATP citrate lyase: Activation and therapeutic implications
in non-small cell lung cancer. Cancer Res. 68:8547–8554. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Chajes V, Cambot M, Moreau K, Lenoir GM
and Joulin V: Acetyl-CoA carboxylase alpha is essential to breast
cancer cell survival. Cancer Res. 66:5287–5294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Carrer A, Trefely S, Zhao S, Campbell SL,
Norgard RJ, Schultz KC, Sidoli S, Parris JLD, Affronti HC, Sivanand
S, et al: Acetyl-CoA metabolism supports multistep pancreatic
tumorigenesis. Cancer Discov. 9:416–435. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zaidi N, Swinnen JV and Smans K:
ATP-citrate lyase: A key player in cancer metabolism. Cancer Res.
72:3709–3714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hatzivassiliou G, Zhao F, Bauer DE,
Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA and
Thompson CB: ATP citrate lyase inhibition can suppress tumor cell
growth. Cancer Cell. 8:311–321. 2005. View Article : Google Scholar
|
|
81
|
Lin R, Tao R, Gao X, Li T, Zhou X, Guan
KL, Xiong Y and Lei QY: Acetylation stabilizes ATP-citrate lyase to
promote lipid biosynthesis and tumor growth. Mol Cell. 51:506–518.
2013. View Article : Google Scholar
|
|
82
|
Niu J, Sun Y, Chen B, Zheng B, Jarugumilli
GK, Walker SR, Hata AN, Mino-Kenudson M, Frank DA and Wu X: Fatty
acids and cancer-amplified ZDHHC19 promote STAT3 activation through
S-palmitoylation. Nature. 573:139–143. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Mashima T, Oh-hara T, Sato S, Mochizuki M,
Sugimoto Y, Yamazaki K, Hamada J, Tada M, Moriuchi T, Ishikawa Y,
et al: p53-defective tumors with a functional apoptosome-mediated
pathway: A new therapeutic target. J Natl Cancer Inst. 97:765–777.
2005. View Article : Google Scholar
|
|
84
|
Yarla NS, Bishayee A, Sethi G, Reddanna P,
Kalle AM, Dhananjaya BL, Dowluru KS, Chintala R and Duddukuri GR:
Targeting arachidonic acid pathway by natural products for cancer
prevention and therapy. Semin Cancer Biol. 40–41:48–81. 2016.
View Article : Google Scholar
|
|
85
|
Murray M, Hraiki A, Bebawy M, Pazderka C
and Rawling T: Anti-tumor activities of lipids and lipid analogues
and their development as potential anticancer drugs. Pharmacol
Ther. 150:109–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Vannitamby A, Saad MI, Aloe C, Wang H,
Kumar B, Vlahos R, Selemidis S, Irving L, Steinfort D, Jenkins BJ
and Bozinovski S: Aspirin-triggered resolvin D1 reduces
proliferation and the neutrophil to lymphocyte ratio in a mutant
KRAS-driven lung adenocarcinoma model. Cancers (Basel).
13:32242021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Riedl K, Krysan K, Pold M, Dalwadi H,
Heuze-Vourc'h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, et
al: Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug
Resist Updat. 7:169–184. 2004. View Article : Google Scholar
|
|
88
|
Xin C, Chu L, Zhang L, Geng D, Wang Y, Sun
D, Sui P, Zhao X, Gong Z, Sui M and Zhang W: Expression of
cytosolic phospholipase A2 (cPLA2)-arachidonic acid
(AA)-Cyclooxygenase-2 (COX-2) pathway factors in lung cancer
patients and its implication in lung cancer early detection and
prognosis. Med Sci Monit. 25:5543–5551. 2019. View Article : Google Scholar
|
|
89
|
Yue S, Li J, Lee SY, Lee HJ, Shao T, Song
B, Cheng L, Masterson TA, Liu X, Ratliff TL and Cheng JX:
Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT
activation underlies human prostate cancer aggressiveness. Cell
Metab. 19:393–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Kopecka J, Trouillas P, Gasparovic AC,
Gazzano E, Assaraf YG and Riganti C: Phospholipids and cholesterol:
Inducers of cancer multidrug resistance and therapeutic targets.
Drug Resist Updat. 49:1006702020. View Article : Google Scholar
|
|
91
|
Yeganeh B, Wiechec E, Ande SR, Sharma P,
Moghadam AR, Post M, Freed DH, Hashemi M, Shojaei S, Zeki AA and
Ghavami S: Targeting the mevalonate cascade as a new therapeutic
approach in heart disease, cancer and pulmonary disease. Pharmacol
Ther. 143:87–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Gorin A, Gabitova L and Astsaturov I:
Regulation of cholesterol biosynthesis and cancer signaling. Curr
Opin Pharmacol. 12:710–716. 2012. View Article : Google Scholar
|
|
93
|
Li D, Long W, Huang R, Chen Y and Xia M:
27-Hydroxycholesterol inhibits sterol regulatory element-binding
protein 1 activation and hepatic lipid accumulation in mice.
Obesity (Silver Spring). 26:713–722. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Nelson ER, Wardell SE, Jasper JS, Park S,
Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V,
et al: 27-Hydroxycholesterol links hypercholesterolemia and breast
cancer pathophysiology. Science. 342:1094–1098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Wang B and Tontonoz P: Liver X receptors
in lipid signalling and membrane homeostasis. Nat Rev Endocrinol.
14:452–463. 2018. View Article : Google Scholar
|
|
96
|
Gibson DA, Collins F, Cousins FL, Esnal
Zufiaurre A and Saunders PTK: The impact of 27-hydroxycholesterol
on endometrial cancer proliferation. Endocr Relat Cancer.
25:381–391. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wu Y, Yu DD, Hu Y, Cao HX, Yu SR, Liu SW
and Feng JF: LXR ligands sensitize EGFR-TKI-resistant human lung
cancer cells in vitro by inhibiting Akt activation. Biochem Biophys
Res Commun. 467:900–905. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Lo Sasso G, Bovenga F, Murzilli S,
Salvatore L, Di Tullio G, Martelli N, D'Orazio A, Rainaldi S, Vacca
M, Mangia A, et al: Liver X receptors inhibit proliferation of
human colorectal cancer cells and growth of intestinal tumors in
mice. Gastroenterology. 144:1497–1507. 1507e1–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Hiramitsu S, Ishikawa T, Lee WR, Khan T,
Crumbley C, Khwaja N, Zamanian F, Asghari A, Sen M, Zhang Y, et al:
Estrogen receptor beta-mediated modulation of lung cancer cell
proliferation by 27-hydroxycholesterol. Front Endocrinol
(Lausanne). 9:4702018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhang L, Liu M, Liu J, Li X, Yang M, Su B
and Lin Y: 27-Hydroxycholesterol enhanced osteoclastogenesis in
lung adenocarcinoma microenvironment. J Cell Physiol.
234:12692–12700. 2019. View Article : Google Scholar
|
|
101
|
Chen Q, Pan Z, Zhao M, Wang Q, Qiao C,
Miao L and Ding X: High cholesterol in lipid rafts reduces the
sensitivity to EGFR-TKI therapy in non-small cell lung cancer. J
Cell Physiol. 233:6722–6732. 2018. View Article : Google Scholar
|
|
102
|
Li J, Yan H, Zhao L, Jia W, Yang H, Liu L,
Zhou X, Miao P, Sun X, Song S, et al: Inhibition of SREBP increases
gefitinib sensitivity in non-small cell lung cancer cells.
Oncotarget. 7:52392–52403. 2016. View Article : Google Scholar
|
